# TP53 in Cancer Overview

This section brings together TP53 testing, interpretation, variant and mutation types, treatment-planning implications, and practical support ideas.

It is organised around the key distinctions that matter most in practice: germline versus somatic findings, common SNP-level variation versus pathogenic mutations, and mutation type rather than gene name alone.

### Start here

If you are new to this topic, follow this order:

1. [Why Test Type Matters](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/why-test-type-matters.md)
2. [TP53 SNPs and Nutrigenomics](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-snps-and-nutrigenomics.md)
3. [Germline TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/germline-tp53.md)
4. [Somatic TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53.md)
5. [TP53 Mutation Types Reference](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53/tp53-mutation-types-reference.md)

That sequence gives the clearest learning flow.

It starts with the common test-type issue, then moves from common lower-impact variation into inherited high-impact findings, then into tumour-acquired mutations.

### Core interpretation pages

* [Why Test Type Matters](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/why-test-type-matters.md)\
  Why a TP53 result means very little until you know whether it came from a nutrigenomic report, a hereditary panel, or a tumour test.
* [TP53 SNPs and Nutrigenomics](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-snps-and-nutrigenomics.md)\
  Common TP53 variation, rs1042522, and the wider DNA-repair context that is most actionable through diet, nutrients, and exposure reduction.
* [Germline TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/germline-tp53.md)\
  Inherited TP53 findings, Li-Fraumeni-spectrum implications, treatment-planning relevance, and why this question can matter before radiotherapy or genotoxic chemotherapy.
* [Somatic TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53.md)\
  Tumour-acquired TP53 mutations, report interpretation, tissue versus liquid biopsy, and what the tumour is actually doing now.
  * [TP53 Mutation Types Reference](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53/tp53-mutation-types-reference.md)\
    Practical decoder for hotspot missense mutations, partial-loss variants, frameshift and nonsense mutations, splice variants, and null states.

### Tests ordered and received, now what?

* [Food and Lifestyle Support](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/food-and-lifestyle-support.md)\
  Realistic support around DNA repair, inflammation, oxidative load, and micronutrients without overclaiming what lifestyle can do.
* [Questions for Oncologists](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/nac-in-p53-mutant-cancers.md)\
  Practical questions to bring into the clinic when results are discussed, so the test type, mutation class, and treatment implications actually get discussed.

### Strategy-related pages

* [Fenbendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/fenbendazole-and-tp53.md)\
  Why tumour wild-type versus mutant or null p53 can change how favourable the fenbendazole biology looks.
* [Mebendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/mebendazole-and-tp53.md)\
  Why mebendazole appears less dependent on intact p53 than fenbendazole, while still engaging p53 pathways in some models.
* [Andrographis and Mutant p53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/andrographis-and-mutant-p53.md)\
  Educational overview of the mutant-p53 clean-up pulse idea, including the Hsp70-proteasome rationale and the main safety cautions.
* [NAC in p53-Mutant Cancers](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/questions-for-oncologists.md)\
  Why NAC may raise more concern in stable gain-of-function mutant-protein states than in p53-null settings.

### How to use this section

Use this hub in one of three ways:

1. **To decode a report**\
   Start with test type, then find the mutation class.
2. **To understand treatment implications**\
   Focus on the germline versus somatic split first.
3. **To explore support ideas more carefully**\
   Read the mutation pages before the strategy pages, so the biology stays matched to the intervention.

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-in-cancer-overview.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.